2013
DOI: 10.1136/ejhpharm-2013-000276.358
|View full text |Cite
|
Sign up to set email alerts
|

PHC-013 Experience with Cannabinoid Treatment

Abstract: Background The oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is an established secondline treatment for advanced non-small cell lung cancer (NSCLC). Erlotinib delays disease progression and increases survival after first-line chemotherapy in patients with advanced NSCLC as second-line treatment. Maintenance treatment with erlotinib, when compared to placebo, could be associated with a significantly longer progression-free survival and tolerability mainly in EGFRactivati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance